Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment
In patients hospitalized with COVID-19, treatment with nMAbs did not decrease long-term anti-nucleocapsid response compared to placebo, suggesting neutralizing therapies do not suppress the endogenous humoral immune response in this population.
Authors
- Robin Dewar (ORCID: https://orcid.org/0000-0002-7840-3155)
- Nayon Kang
- Sylvain Laverdure (ORCID: https://orcid.org/0000-0002-8053-4891)
- Amy Weintrob (ORCID: https://orcid.org/0000-0002-4626-5317)
- Vidya Menon (ORCID: https://orcid.org/0000-0003-1411-3420)
- Barnaby Edward Young (ORCID: https://orcid.org/0000-0003-1010-2230)
- Nicole Engen (ORCID: https://orcid.org/0000-0003-1118-4194)
- Tauseef Ur Rehman (ORCID: https://orcid.org/0000-0001-6939-8027)
- Anna L. Goodman (ORCID: https://orcid.org/0000-0003-0643-9017)
- Hallie C. Prescott (ORCID: https://orcid.org/0000-0002-8442-6724)
- Timothy Hatlen (ORCID: https://orcid.org/0000-0003-3755-4309)
- Tomas Ø. Jensen (ORCID: https://orcid.org/0000-0003-0398-4431)
- Ravi K. Patel (ORCID: https://orcid.org/0000-0001-5203-899X)
- Anne P. Frosch
- David M. Vock (ORCID: https://orcid.org/0000-0002-5459-9579)
- Prasad Manian
- Thomas L Holland (ORCID: https://orcid.org/0000-0001-7745-9010)
- Srikanth Ramachandruni
- Thomas Barrett (ORCID: https://orcid.org/0000-0001-7083-5407)
- Birgit Thorup Røge (ORCID: https://orcid.org/0000-0003-2170-7665)
- Gareth Hughes (ORCID: https://orcid.org/0000-0003-2942-6489)
- Elizabeth S. Munroe (ORCID: https://orcid.org/0000-0003-3353-612X)
- Muhammad Attique Khan (ORCID: https://orcid.org/0000-0002-6347-4890)
- Kathryn Shaw-Saliba
- Robert C. Hyzy
- Ioannis Kalomenidis
- Helene Highbarger
- Greg Grandits
Institutions
- Leidos (United States) (US)
- New York City Health and Hospitals Corporation (US)
- University of Minnesota (US)
- Duke University (US)
- Baylor College of Medicine (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- Veterans Health Administration (US)
- UCLA Medical Center (US)
- Clinical Research Institute (US)
- MRC Clinical Trials Unit at UCL (GB)
- Bay Pines VA Healthcare System (US)
- Michigan United (US)
- CHRISTUS Spohn Hospital Corpus Christi - Memorial (US)
- Michigan Medicine (US)
- VA Center for Clinical Management Research (US)
- Kolding Hospital (DK)
- Frederick National Laboratory for Cancer Research (US)
- National Institute of Allergy and Infectious Diseases (US)
- VA Portland Health Care System (US)
- National Centre for Infectious Diseases (SG)
- Hennepin Healthcare Research Institute (US)
- Washington DC VA Medical Center (US)
- Centre of Excellence for Health, Immunity and Infections (DK)
- Harbor–UCLA Medical Center (US)
- University College London (GB)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1371/journal.pone.0325561
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Foundation for the National Institutes of Health
- U.S. Department of Veterans Affairs
- Pfizer
- Sanofi
- Gilead Sciences
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Leidos
- Moderna
- National Research Foundation Singapore
- National Institutes of Health
- Medical Research Council
- National Medical Research Council
- National Heart, Lung, and Blood Institute
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research